000274211 001__ 274211
000274211 005__ 20240229154929.0
000274211 0247_ $$2doi$$a10.1007/s00259-023-06185-5
000274211 0247_ $$2pmid$$apmid:36905411
000274211 0247_ $$2ISSN$$a1619-7070
000274211 0247_ $$2ISSN$$a0340-6997
000274211 0247_ $$2ISSN$$a1432-105X
000274211 0247_ $$2ISSN$$a1619-7089
000274211 0247_ $$2altmetric$$aaltmetric:143798646
000274211 037__ $$aDKFZ-2023-00497
000274211 041__ $$aEnglish
000274211 082__ $$a610
000274211 1001_ $$aSolomonidou, Nantia$$b0
000274211 245__ $$aPSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
000274211 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2023
000274211 3367_ $$2DRIVER$$aarticle
000274211 3367_ $$2DataCite$$aOutput Types/Journal article
000274211 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1686641822_12253
000274211 3367_ $$2BibTeX$$aARTICLE
000274211 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274211 3367_ $$00$$2EndNote$$aJournal Article
000274211 500__ $$a2023 Jul;50(8):2529-2536
000274211 520__ $$aThe purpose of this retrospective, multicenter study was to assess efficacy of PSMA-PET/CT-guided salvage radiotherapy (sRT) in patients with recurrent or persistent PSA after primary surgery and PSA levels < 0.2 ng/ml.The study included patients from a pooled cohort (n = 1223) of 11 centers from 6 countries. Patients with PSA levels > 0.2 ng/ml prior to sRT or without sRT to the prostatic fossa were excluded. The primary study endpoint was biochemical recurrence-free survival (BRFS) and BR was defined as PSA nadir after sRT + 0.2 ng/ml. Cox regression analysis was performed to assess the impact of clinical parameters on BRFS. Recurrence patterns after sRT were analyzed.The final cohort consisted of 273 patients; 78/273 (28.6%) and 48/273 (17.6%) patients had local or nodal recurrence on PET/CT. The most frequently applied sRT dose to the prostatic fossa was 66-70 Gy (n = 143/273, 52.4%). SRT to pelvic lymphatics was delivered in 87/273 (31.9%) patients and androgen deprivation therapy was given to 36/273 (13.2%) patients. After a median follow-up time of 31.1 months (IQR: 20-44), 60/273 (22%) patients had biochemical recurrence. The 2- and 3-year BRFS was 90.1% and 79.2%, respectively. The presence of seminal vesicle invasion in surgery (p = 0.019) and local recurrences in PET/CT (p = 0.039) had a significant impact on BR in multivariate analysis. In 16 patients, information on recurrence patterns on PSMA-PET/CT after sRT was available and one had recurrent disease inside the RT field.This multicenter analysis suggests that implementation of PSMA-PET/CT imaging for sRT guidance might be of benefit for patients with very low PSA levels after surgery due to promising BRFS rates and a low number of relapses within the sRT field.
000274211 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000274211 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000274211 650_7 $$2Other$$aPSMA-PET
000274211 650_7 $$2Other$$aProstate cancer
000274211 650_7 $$2Other$$aProstate-specific antigen
000274211 650_7 $$2Other$$aSalvage radiotherapy
000274211 7001_ $$aGermanou, Daphnie$$b1
000274211 7001_ $$aStrouthos, Iosif$$b2
000274211 7001_ $$aKaragiannis, Efstratios$$b3
000274211 7001_ $$aFarolfi, Andrea$$b4
000274211 7001_ $$0P:(DE-HGF)0$$aKoerber, Stefan A$$b5
000274211 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b6$$udkfz
000274211 7001_ $$0P:(DE-HGF)0$$aPeeken, Jan C$$b7
000274211 7001_ $$0P:(DE-HGF)0$$aVogel, Marco E$$b8
000274211 7001_ $$aVrachimis, Alexis$$b9
000274211 7001_ $$0P:(DE-HGF)0$$aSpohn, Simon K B$$b10
000274211 7001_ $$aShelan, Mohamed$$b11
000274211 7001_ $$aAebersold, Daniel$$b12
000274211 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b13
000274211 7001_ $$aCeci, Francesco$$b14
000274211 7001_ $$aKroeze, Stephanie G C$$b15
000274211 7001_ $$aGuckenberger, Matthias$$b16
000274211 7001_ $$aFanti, Stefano$$b17
000274211 7001_ $$aBelka, Claus$$b18
000274211 7001_ $$aHruby, George$$b19
000274211 7001_ $$aScharl, S.$$b20
000274211 7001_ $$aWiegel, Thomas$$b21
000274211 7001_ $$aBartenstein, Peter$$b22
000274211 7001_ $$aHenkenberens, Christoph$$b23
000274211 7001_ $$aEmmett, Louise$$b24
000274211 7001_ $$aSchmidt-Hegemann, Nina Sophie$$b25
000274211 7001_ $$aFerentinos, Konstantinos$$b26
000274211 7001_ $$00000-0002-7849-7550$$aZamboglou, Constantinos$$b27
000274211 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-023-06185-5$$n8$$p2529-2536$$tEuropean journal of nuclear medicine and molecular imaging$$v50$$x1619-7070$$y2023
000274211 909CO $$ooai:inrepo02.dkfz.de:274211$$pVDB
000274211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000274211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000274211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000274211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000274211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000274211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000274211 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-7849-7550$$aDeutsches Krebsforschungszentrum$$b27$$kDKFZ
000274211 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000274211 9141_ $$y2023
000274211 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-23$$wger
000274211 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-23$$wger
000274211 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-23
000274211 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-23
000274211 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2023-08-23
000274211 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000274211 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000274211 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-23
000274211 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-23
000274211 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000274211 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000274211 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-23
000274211 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-23
000274211 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2023-08-23
000274211 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000274211 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK MU LMU zentral$$x1
000274211 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x2
000274211 980__ $$ajournal
000274211 980__ $$aVDB
000274211 980__ $$aI:(DE-He78)E050-20160331
000274211 980__ $$aI:(DE-He78)MU01-20160331
000274211 980__ $$aI:(DE-He78)FR01-20160331
000274211 980__ $$aUNRESTRICTED